nutraceutical glp 1 Resbiotic Launches ResM GLP-1 Postbiotic GLP-1 and Nutraceuticals: Appetite Control
Description
In contrast, in 2018, the long-acting GIPGLP-1 co-agonist tirzepatide was found to have substantial glucose-lowering and weight loss properties, to a greater extent than that achieved by GLP-1R agonism with dulaglutide [68], findings replicated in Phase III trials comparing tirzepatide with semaglutide in people with type 2 diabetes [69]

There is an increased risk of hypoglycaemia in patients using concurrent hypoglycaemic agents (e.g
This result suggests a potential direct effect of exenatide on lipedematous tissue, also supported by the fact that the degree of insulin resistance in this patient was minimal

If you are considering switching due to plateau, exploring why you are not losing weight on your current medication may reveal other factors at play
However, considerations around kidney function monitoring, hydration status, and body composition tracking warrant careful clinical evaluation when using both concurrently
Genetic testing completed during your first month of treatment allows your clinician to pivot your formulation or dosing strategy based on your unique peptide pathway responsiveness, maximizing weight loss while minimizing GI distress
